ESCITALOPRAM OXALATE - PsychMedIndex

Basic Information

FDA Status

FDA Approved

Mechanism of Action

12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action The mechanism of antidepressant action of escitalopram, the S-enantiomer of racemic citalopram, is presumed to be linked to potentiation of serotonergic activity in the central nervous system (CNS) resulting from its inhibition of CNS neuronal reuptake of serotonin (5-HT). 12.2 Pharmacodynamics In vitro and in vivo studies in animals suggest that escitalopram is a highly selective serotonin reuptake inhibitor (SSRI) with minimal effects on norepi...

⚠️ Black Box Warning

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.1) ] . Escitalopram oxalate is not approved for use in pediatric patients less than 12 years of age [see Use in Specific Populations (8.4) ]. WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Increased risk of suicidal thoughts and behavior in pediatric and young adult patients taking antidepressants. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors (5.1). Escitalopram oxalate is not approved for use in pediatric patients less than 12 years of age ( 8.4 ).

Conditions Treated

1 INDICATIONS AND USAGE Escitalopram oxalate is a selective serotonin reuptake inhibitor (SSRI) indicated for: Acute and Maintenance Treatment of Major Depressive Disorder (MDD) in adults and adolescents aged 12 to 17 years (1.1) Acute Treatment of Genera
FDA Approved Evidence: Strong

Target Populations / Best Suited For

Second Line

Adlts

Contraindications

Relative
4 CONTRAINDICATIONS Serotonin Syndrome and MAOIs: Do not use MAOIs intended to treat psychiatric disorders with escitalopram tablets or within 14 days of stopping treatment with escitalopram tablets. Do not use escitalopram tablets within 14 days of stopping an MAOI intended to treat psychiatric disorders. In addition, do not start escitalopram tablets in a patient who is being treated with linezolid or intravenous methylene blue (4.1) . Pimozide: Do not use concomitantly ( 4.2 ). Known hypersen

📚 Recent Research (PubMed)

Mindfulness-Based Stress Reduction vs Escitalopram for the Treatment of Adults With Anxiety Disorders: A Randomized Clinical Trial.

Authors: Hoge EA, Bui E, Mete M et al.
Journal: JAMA Psychiatry (2023 Jan 1)

Read on PubMed →

Escitalopram versus other antidepressive agents for major depressive disorder: a systematic review and meta-analysis.

Authors: Yin J, Song X, Wang C et al.
Journal: BMC Psychiatry (2023 Nov 24)

Read on PubMed →

Increased global integration in the brain after psilocybin therapy for depression.

Authors: Daws RE, Timmermann C, Giribaldi B et al.
Journal: Nat Med (2022 Apr)

Read on PubMed →

Escitalopram in Adolescents With Generalized Anxiety Disorder: A Double-Blind, Randomized, Placebo-Controlled Study.

Authors: Strawn JR, Mills JA, Schroeder H et al.
Journal: J Clin Psychiatry (2020 Aug 25)

Read on PubMed →

Psychedelic drugs in the treatment of psychiatric disorders.

Authors: Ibrahim IB, Videbech P, Straszek SPV et al.
Journal: Ugeskr Laeger (2023 Aug 7)

Read on PubMed →

🔗 External Resources

💊 Drugs.com 🏥 WebMD 💰 GoodRx Pricing 🏛️ Mayo Clinic 📋 DailyMed (FDA) 📖 RxList

🤖 AI Research Assistant

Get real-time research and insights about ESCITALOPRAM OXALATE from across the web, synthesized by AI.